Lotus Pharmaceutical Co., Ltd. 1795

Alvotech stock has fallen about 50% over the past three years, yet the valuation checks currently lean cheap and the market is reacting positively to fresh licensing deals and regulatory progress. Over the past three years the share price is down about 50%, which means any case for owning Alvotech today rests heavily on a potential recovery from a deep drawdown. A recent licensing agreement with Lotus Pharmaceutical for two biosimilars and ongoing work toward U.S. approvals can support...

In August 2026, Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for biosimilar candidates AVT34 (Imfinzi) and AVT87 (Hemlibra) across the United States and eight Asian markets, with potential consideration of up to approximately US$150 million plus ongoing supply revenues. The deal expands Alvotech’s access to oncology and hematology markets while keeping it in control of development, regulatory approvals, and global product supply. We’ll now examine...